Sampling of dermal Interstitial Fluid (dISF)

About us

With the tremendous breakthroughs achieved in analysis methods, the guidance received from number crunching apps and the awareness that comes from our connected modern lifestyle with a smart device always at arm’s reach; The missing link has been the very first part of the chain - How to get biomarkers out of the body using methods compatible with our modern way of life?  

Who we are

Founded on the premise of radically improving healthcare, the team set out to develop hollow microneedles that can sample dermal interstitial fluid in a pain-free and easy to use way.
After almost 10 years of development, the company is entering into numerous clinical trials with the aim of characterizing both the system and dISF itself.

How we work

Ascilion has developed a platform technology for sampling of dermal interstitial fluid. We collaborate with partners in all segments of life sciences on customized versions of the product tailored towards the application at hand. The core of all products is a chipset with a plurality of hollow microneedles and an application-optimized collection system for the sampled fluid.
Sampling of dISF has never been easier with on-screen monitoring, precise sub-pressure control and pre-defined sampling sequences.

How it began

Ascilion was founded in 2012 with a mission to solve the problem of sampling dermal interstitial fluid in a timely and pain-free way. A team of engineers with a thorough understanding of MEMS technology and microfluidics took on the challenge of solving what turned out to be a very complex problem.

”We are impressed by Ascilion’s technology platform and by the team behind the company. Ascilion’s products are at the forefront and can contribute to developing and improving today’s diagnostic methods. Nordstjernan’s ambition is to continue growing in the health sector, and medical technology and diagnostics are areas we actively want to invest in. We look forward to supporting Ascilion in the company’s future development,” says Nordstjernan’s CEO Peter Hofvenstam.

- Dagens Industri, Nordstjernan

Lorum ipsum

Lorum ipsum dolor sit amet. Sed dium nonum nibb euismod tincidunt ut laorect dolore magna aliquam erat volutpat. Ust wist enim ad minim. Venium quis nostrud exertci tation. Lorum ipsum dolor sit amet. Sed dium nonum nibb euismod tincidunt ut laorect dolore magna aliquam erat volutpat.

News

March 25, 2024
Dermal ISF sampling abstract presented by Charité and Fraunhofer at the 2024 ADF meeting in Germany

For the third time Ascilion’s dermal ISF sampling solutions were presented at the annual meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) in Germany.

This year, researchers from the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, and Institute of Allergology (IA), Charité - Universitätsmedizin Berlin, presented the application of Ascilion’s hollow microneedles in a model of chronic inducible urticaria. 

Read the abstract (on page 7):P014 - 15.1 “Application of hollow microneedles in a model of chronic inducible urticaria” (Shi et al. 2024)

Ascilion ADF abstracts from 2024 and previous years can be found here: ADF Abstract Books 

October 13, 2023
Ascilion to exhibit at the Dermatology Drug Development Summit for Inflammatory Skin Diseases in Boston

Ascilion will attend and exhibit at the 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Disease in Boston. The meeting will be held from the 31st October - 2nd November 2023

The conference is specifically for executives from pharmaceutical companies working within drug development in the inflammatory skin disease area. This will be an excellent opportunity for Ascilion to discuss how it's dermal interstitial fluid (dISF) sampling technology can assist pharma companies in their development processes.

For more information on the conference: https://ter.li/b201q6

October 3
Ascilion appoints Simon Grant as Chief Executive Officer

STOCKHOLM, SWEDEN, October 3, 2023 /EINPresswire.com/ -- Ascilion AB ("Ascilion") the world leader in interstitial fluid (ISF) sampling for biomarker investigation announced yesterday that the Board has appointed Simon Grant as Chief Executive Officer (CEO).

Simon has extensive Life Science industry experience, having held management positions in smaller startups such as Neoventa and Synectics Medical, and large multinationals such as Medtronic and Sandvik. Most recently Simon held the position of CEO at SciBase AB, a Swedish point-of-care diagnostics company listed on Nasdaq First North, Stockholm.

Sten Dahlborg, Chairman of the Board at Ascilion commented: "We are very happy to welcome Simon as CEO, and his appointment signals a new phase in the development of Ascilion. Simon brings extensive commercialization experience, having developed and introduced more than a dozen new medical technologies in the international market. His enthusiasm towards our technology and its application reinforces our belief in its potential" Furthermore, he added: "I would also like to take the opportunity to thank Markus Renlund for the excellent work he has done to lead the company to this stage. Markus will continue with the Company, both as a Board member and in his role as Technology and Innovation Lead.

Simon Grant commented "In my opinion interstitial fluid sampling has the potential to disrupt the standard of care in multiple clinical specialties and drive significant research and wellness applications. ISF contains a ‘treasure trove’ of biomarker information that until now has been mostly untapped because it is practically so difficult to extract. Ascilion is a world leader in hollow microneedles, and it is that technology that enables us to access ISF in useful volumes for the very first time. I believe that Ascilion has the ability to change the way that things are done clinically and that we can build a significant business around the technology – and this is especially exciting for me.”

For further information visit www.ascilion.com or contact:

Sten Dahlborg, Chairman

Tel: +46 70 836 94 19

or

Simon Grant, CEO

Tel: +46 72 887 43 99

E-post: info@ascilion.com

About Ascilion

Ascilion is the world leader in sampling of dermal interstitial fluid (dISF). A pioneer within hollow microneedle technology since 2012, Ascilion has developed the only solution available for sampling of practical amounts of pure dISF, enabling complete quantitative biomarker evaluation. Ascilion’s technology is painless, quick, easy to use and leaves no residual mark on the skin. Products are available for research use and for pharmaceutical or cosmetic testing applications and are currently undergoing the medical product approval process. We are a cross-functional team based just outside Stockholm, Sweden working closely with industry-leading customers in several target segments.

May 22, 2023
Charité – Universitätsmedizin Berlin receives ethical approval for use of Ascilion’s microneedles in a feasibility study at Institute of Allergology (IFA)

Ascilion is pleased to participate in a study at IFA, Charité where part of the study aims to confirm that sub-pressure assisted interstitial fluid (ISF) extraction using hollow microneedles reliably and repeatability yields sufficient volumes of ISF for tryptase, histamine determination and cytokine profiling in response to skin provocation.

May 2023
7th International Conference on Microneedles – MICRONEEDLES 2023 – Seattle, US

The International Microneedle Conference is a global conference comprised of both industrial and academic attendees, and this event has grown steadily since its inception in 2010.

Ascilion is proud to announce its support to the conference by being a Gold Sponsor.

Come and meet part of the Ascilion team at the MICRONEEDLES conference, Hyatt At Olive 8, 1635 8th Ave, Seattle, USA between May 15 – May 17, 2023

www.microneedlesconference.com

Apr 2023
Consortium Meeting 5, DIGIPREDICT Live demonstration of Interstitial Fluid Sampling, Lausanne, Switzerland

Presentations and live demonstration of interstitial fluid sampling was held by Ascilion during the 5th Consortium Meeting in the European Project DIGIPREDICT was held at EPFL, Lausanne Switzerland.

www.digipredict.eu/news

Sept 2022
Charité/Fraunhofer ITMP to present at 9th International Microdialysis Symposium, Berlin, Germany

Representatives from Charité – Universitätsmedizin Berlin and Fraunhofer Institute for Translational Medicine and Pharmacology will present “Application of hollow microneedles for skin ISF harvesting in models of allergy and chronic urticaria”at the 9th International Microdialysis Symposium, 7-9 September, 2022, Berlin, Germany

9th Int Symp on Microdialysis

Jan 2022
Nordstjernan to invest in medtech company Ascilion

Nordstjernan is investing in Ascilion, a Swedish medtech company founded in 2012 and based in Stockholm, Sweden. Ascilion has developed and patented a technology that uses an array of hollow microneedles to extract the interstitial fluid (ISF) that surrounds the body’s cells and that is a good carrier of biomarkers. Ascilion’s technology has numerous fields of application, including within several branches of medical diagnostics. Nordstjernan will become the second largest owner in Ascilion and, as a partner to the company’s founder and current owners, the aim is to accelerate the company’s commercial development.

“We are impressed by Ascilion’s technology platform and by the team behind the company. Ascilion’s products are at the leading edge and can help develop and improve current diagnostic methods. Nordstjernan’s ambition is to continue growing in the health sector, and medtech and diagnostics are fields in which we want to actively invest. We look forward to supporting Ascilion in the company’s future development,”

says Nordstjernan’s CEO Peter Hofvenstam.

www.nordstjernan.se/nyheter

Jan 2021
Launch of the EU-project DIGIPREDICT

DIGIPREDICT is a pan-European research program bringing together scientific and technical excellence in multiple disciplines including informatics (machine learning), engineering (embedded systems, sensors, and wearables), medical science (organ-on-chip systems, digital medicine), translational science (clinical studies and research), ethical and regulatory frameworks. The consortium consists of three members from academia (EPFL, UTWENTE & ETHZ), two large R&D institutes (IMEC-BE & IMEC-NL), two hospitals (Charité & UBERN), two high-tech SMEs (Ascilion and EPOS) and a management and communication SME (SCIPROM) from five European countries.

Ascilion´s role in the project will be to design and manufacture chips with arrays of ultra-sharp, hollow microneedles in monocrystalline silicon using micro-electro-mechanical system (MEMS) technology.

The DIGIPREDICT, funded by the European Union's Horizon 2020 research and innovation programme, started on 1 January 2021 and will run until 31 December 2024

Press release - DIGIPREDICT´s coordinator

Nov 2020
6th International Conference on Microneedles – MICRONEEDLES 2020 – on-line/South Korea

Presentations: “Interstitial Fluid Extracted using Hollow Microneedles - Comparison of Lipid Content in ISF vs Whole Blood”, “Sub-pressure Assisted Application of Sharp Hollow Microneedles Improves Penetration”.

https://www.microneedles2020.org/

May 2018
5th International Conference on Microneedles – MICRONEEDLES 2018 – Vancouver, Canada

Presentation: “Rapid Extraction of Interstitial Fluid using Sharp Hollow Silicon Microneedles”

www.microneedles2018.org

May 2016
4th International Conference on Microneedles – MICRONEEDLES 2016 – London, UK

Presentation: “High-yield and High-volume Fabrication of Silicon Microneedles Intended for Interstitial Fluid Extraction”

Feb 2016
9th International Conference on Advanced Technologies & Treatments for Diabetes – ATTD – Milan, Italy

Presentation: “Extraction of Interstitial Fluid and Sensing of Glucose Levels using Microneedles and Millimetre Wave Spectroscopy”

Get in touch

Contact us